The List of Drugs Approved by the FDA in 2019

The US FDA approved 42 novel drugs in 2019. This was down from 59 approved in 2018. Swiss pharma giant (NVS) was the only company with four drugs approved. The complete list of drugs approved by the FDA in 2019 are shown in the table below:

No. Drug Name  Active Ingredient Approval Date FDA-approved use on approval date*
48. Ubrelvy ubrogepant 12/23/2019 to treat acute treatment of migraine with or without aura in adults
Press Release
Drug Trials Snapshot
47. Enhertu fam-trastuzumab deruxtecan-nxki 12/20/2019 To treat metastatic breast cancer
Press Release
Drug Trials Snapshot
46 Dayvigo lemborexant 12/20/2019 To treat insomnia
Drug Trials Snapshot
45. Caplyta lumateperone tosylate 12/20/2019 To treat schizophrenia
Drug Trials Snapshot
44. TissueBlue Brilliant Blue G Ophthalmic Solution 12/20/2019 Dye used in eye surgery
Drug Trials Snapshot
43. Padcev enfortumab vedotin-ejfv 12/18/2019 To treat refractory bladder cancer
Press Release
Drug Trials Snapshot
42. Vyondys 53 golodirsen 12/12/2019 To treat certain patients with Duchenne muscular dystrophy
Press Release
Drug Trials Snapshot
41. Oxbryta voxelotor 11/25/2019 To treat sickle cell disease
Press Release
Drug Trials Snapshot
40. Xcopri cenobamate 11/21/2019 To treat partial onset seizures
Press Release
Drug Trials Snapshot
39. Givlaari givosiran 11/20/2019 To treat acute hepatic porphyria, a rare blood disorder
Press Release
Drug Trials Snapshot
38. Adakveo crizanlizumab-tmca 11/15/2019 To treat patients with painful complication of sickle cell disease
Press Release
Drug Trials Snapshot
37. Fetroja cefiderocol 11/14/2019 To treat patients with complicated urinary tract infections who have limited or no alternative treatment options
Press Release
Drug Trials Snapshot
36. Brukinsa zanubrutinib 11/14/2019 To treat certain patients with mantle cell lymphoma, a form of blood cancer
Press Release
Drug Trials Snapshot
35. Reblozyl luspatercept–aamt 11/8/2019 For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions
Press Release
Drug Trials Snapshot
34. ExEm Foam air polymer-type A 11/7/2019 A diagnostic agent used to assess fallopian tube patency (openness) in women with known or suspected infertility
Drug Trials Snapshot
33. Trikafta elexacaftor/ivacaftor/tezacaftor 10/21/2019 To treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosis
Press Release
Drug Trials Snapshot
32. Reyvow lasmiditan 10/11/2019 For the acute treatment of migraine with or without aura, in adults
Press Release
Drug Trials Snapshots
31. fluorodopa F 18 10/10/2019 A diagnostic agent for use in positron emission tomography (PET) to help diagnose adult patients with suspected Parkinsonian syndromes (PS)
Drug Trials Snapshot
30. Scenesse afamelanotide 10/8/2019 To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria
Press Release
Drug Trials Snapshot
29. Beovu brolucizumab–dbll 10/7/2019 Treatment of wet age-related macular degeneration
Drug Trials Snapshot
28. Aklief trifarotene 10/4/2019 For the topical treatment of acne vulgaris in patients 9 years of age and older
Drug Trials Snapshot
27. Ibsrela tenapanor 9/12/2019 To treat irritable bowel syndrome with constipation in adults.
Drug Trials Snapshot
26. Nourianz istradefylline 8/27/2019 To treat adult patients with Parkinson’s disease experiencing “off” episodes
Press Release
Drug Trials Snapshot
25. Ga-68-DOTATOC Ga-68-DOTATOC 8/21/2019 For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs)
Drug Trials Snapshot
24. Xenleta lefamulin 8/19/2019 To treat adults with community-acquired bacterial pneumonia
Press Release
Drug Trials Snapshot
23. Rinvoq upadacitinib 8/16/2019 To treat adults with moderately to severely active rheumatoid arthritis
Drug Trials Snapshot
22. Inrebic fedratinib 8/16/2019 To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
Press Release
Drug Trials Snapshot
21. Rozlytrek entrectinib 8/15/2019 To treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive
To treat adult and pediatric patients 12 years of age and older with solid tumors
Press Release
Drug Trials Snapshot: Pediatric patients 12 years of age and older with solid tumors
Drug Trials Snapshot: Metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive
20. Wakix pitolisant 8/14/2019 To treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy
Drug Trials Snapshot
19. pretomanid 8/14/2019 For treatment-resistant forms of tuberculosis that affects the lungs
Press Release
Drug Trials Snapshot
18. Turalio pexidartinib 8/2/2019 To treat adult patients with symptomatic tenosynovial giant cell tumor
Press Release
Drug Trials Snapshot
17. Nubeqa darolutamide 7/30/2019 To treat adult patients with non-metastatic castration resistant prostate cancer
Drug Trials Snapshot
16. Accrufer ferric maltol 7/25/2019 To treat iron deficiency anemia in adults
Drug Trials Snapshot
15. Recarbrio imipenem, cilastatin and relebactam 7/16/2019 To treat complicated urinary tract and complicated intra-abdominal infections
Press Release
Drug Trials Snapshot
14. Xpovio selinexor 7/3/2019 To treat adult patients with relapsed or refractory multiple myeloma (RRMM)
Press Release
Drug Trials Snapshot
13. Vyleesi bremelanotide 6/21/2018 To treat hypoactive sexual desire disorder in premenopausal women.
Press Release
Drug Trials Snapshot 
12. Polivy polatuzumab vedotin-piiq 6/10/2019 To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma
Press Release
Drug Trials Snapshot
11. Piqray alpelisib 5/24/2019 To treat breast cancer
Press Release
Drug Trials Snapshot
10. Vyndaqel tafamidis meglumine 5/3/2019 To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults
Press Release 
Drug Trials Snapshot
9. Skyrizi risankizumab-rzaa 4/23/2019 To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Drug Trials Snapshot
8. Balversa erdafitinib 4/12/2019 To treat adult patients with locally advanced or metastatic bladder cancer
Press Release
Drug Trials Snapshot
7. Evenity romosozumab-aqqg 4/9/2019 To treat osteoporosis in postmenopausal women at high risk of fracture
Press Release
Drug Trials Snapshot
6. Mayzent siponimod 3/26/2019 To treat adults with relapsing forms of multiple sclerosis
Press Release
Drug Trials Snapshot
5. Sunosi solriamfetol 3/20/2019 To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
Drug Trials Snapshot
4. Zulresso brexanolone 3/19/2019 To treat postpartum depression (PPD) in adult women
Press Release
Drug Trials Snapshot
3. Egaten triclabendazole 2/13/2019 To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”
Drug Trials Snapshot
2. Cablivi caplacizumab-yhdp 2/6/2019 To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP)
Press Release
Drug Trials Snapshot
 1.  Jeuveau prabotulinumtoxinA-xvfs  2/1/2019  For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients

Source: FDA

For more details you can visit the FDA site.

Disclosure: No Positions

Doctors per Capita is the Lowest in the US among OECD Countries

Health care in the US is a cruel joke. Among the developed countries, the health care “system” is the worst in the world in terms of pretty much everything from spending to outcomes. One can easily write a voluminous book on the reasons for this disaster that all of us have to deal with. Too many cooks each with its own agenda leads to high cost and not so much improvement in the all important outcome for the patient.

It is possible to get a $0.99 burger anytime in one of the fast joints in the nation. However if one falls sick after eating this and checks into a hospital, he/she can end up paying hundreds even with insurance. One factor that causes health care costs to skyrocket each year is that the supply of doctors are highly restricted. The demand for health care is high but the supply is limited by the American Medical Association. As the number of doctors available is restricted the price of existing doctors goes up naturally for their services. The population of the country increases year after year due to both legal and illegal immigrants. However the number of doctors does not rise accordingly. No wonder the population is forced to deal with physician shortage on a permanent basis.

The following chart shows Doctors per capita in the OECD countries based on 2018 data from a recent research report. The US has the lowest number at just 2.6 doctors per 1,000 people. Norway has the highest at about double that of the US rate.

Click to enlarge

Source: U.S. Health Care from a Global Perspective, 2019: Higher Spending, Worse Outcomes? by Roosa Tikkanen and Melinda K. Abrams, The Commonwealth Fund

From the report:

Despite having the highest level of health care spending, Americans had fewer physician visits than their peers in most countries. At four visits per capita per year, Americans visit the doctor at half the rate as do Germans and the Dutch. The U.S. rate was comparable to that in New Zealand, Switzerland, and Norway, but higher than in Sweden.

Less-frequent physician visits may be related to the low supply of physicians in the U.S. compared with the other countries. The U.S. has slightly more than half as many physicians as Norway, which has the highest supply.

The economic consequence of this cartel-like behavior of restricting doctors supply is huge. For instance, millions of productive hours are wasted by workers trying to get an appointment with doctors and then sitting in the doctor’s office for hours waiting for these god-like humans to see the patient. The moral consequences cannot be estimated as millions of Americans skip necessary doctor visits and some even perish due to lack of access to doctors or healthcare. But then again does anyone really care about morality anymore ?

The Fastest-Growing Global Tourist Destinations 2019

Tourism is an important industry in many countries of the world. The industry accounts for billions of dollars in economic activity and millions of jobs around the world. In some of the small countries such as those in the Caribbean, tourism is the main industry that the country’s economy depends on. Below are some of the fascinating facts related to the economic impacts of Global Tourism:

  • Tourism accounted for 10.4% of global GDP in 2018 (i.e. US $ 8.8 Trillion)
  • One in ten all jobs are related to the industry
  • 1/5 of all new jobs created in the last five years are in Tourism
  • In 2018, after manufacturing tourism was the second growing sector

Source: TRAVEL & TOURISM ECONOMIC IMPACT 2019 WORLD, World Travel & Tourism Council

Countries that ignore tourism as an industry lose substantial revenue.

With that said, the below infographic shows the fastest-growing tourism destinations based on 2019 data:

Click to enlarge

Source: RFE/RL

On the Explosive Growth of Digital Data: Chart

Data is being created at an astonishing rate today.From Youtube to Twitter to everything in between, billions of people around the world are creating content every day. The dramatic growth in social media in recent years has led to the creation of even more data, For example, millions of videos are uploaded onto Youtube, Facebook, etc. every day. According to one IBM report in 2016, the size of the digital universe may reach a Brontobyte in the coming decade.

How big is a Brontobyte? The following chart shows the answer:

Click to enlarge

Source: What’s causing the exponential growth of data? by Timoth Greaton, Nikko Asset Management

From the above article:

One of the most interesting statistics about the increasing volume of data appeared in a 2016 IBM report “10 Key Marketing Trends For 2017”, which outlined that 90% of all worldwide data at that time was created in the preceding two years, when 2.5 quintillion bytes of data was created per day. With data volume around the world still growing at an immense pace, it could be a matter of time before the global datasphere reaches a brontobyte (approximately 1,024 yottabytes) in the coming decade (Chart 3).

An interesting question to think about is this: Has the exponential growth of data made people smarter or dumber? Or to put differently, has social media made people more intelligent, educated, cultured and responsible citizens (or) has it made them dumb, foolish and mindless zombies cocooned into their own little world?